Free tool
FAERS Monitor: Ivra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217110 or its brand name (Ivra, Melphalan Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
13
Serious
12
92% of reports
Hospitalization
4
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death3
- acute kidney injury1
- adenovirus infection1
- aspiration1
- atrial fibrillation1
- blood creatinine increased1
- cardiomyopathy1
- colitis1
- deep vein thrombosis1
- diarrhoea1
- dry eye1
- enterocolitis infectious1
- fall1
- fatigue1
- febrile neutropenia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2020 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| enterocolitis infectious | 1 | 1756.6 | 266.9 | 438 |
| adenovirus infection | 1 | 558.1 | 84.9 | 138 |
| aspiration | 1 | 147.7 | 22.5 | 36 |
| cardiomyopathy | 1 | 109.5 | 16.7 | 26 |
| colitis | 1 | 42.7 | 6.5 | 10 |
| dry eye | 1 | 32.4 | 4.9 | 7 |
| deep vein thrombosis | 1 | 24.9 | 3.8 | 5 |
| blood creatinine increased | 1 | 24.8 | 3.8 | 5 |
| febrile neutropenia | 1 | 24.4 | 3.7 | 5 |
| atrial fibrillation | 1 | 16.6 | 2.5 | 3 |
| acute kidney injury | 1 | 10.6 | 1.6 | 2 |
| deathSignal | 3 | 5.6 | 2.1 | 8 |
| fall | 1 | 4.9 | 0.7 | 0 |
| diarrhoea | 1 | 2.5 | 0.4 | 0 |
| fatigue | 1 | 2.1 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.